Celldex Therapeutics (Nasdaq:CLDX) - Hisse Senedi Fiyatı, Haberler ve Analizler

CLDX Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Celldex Therapeutics, Inc. çeşitli hastalıkların tedavisi için terapötik monoklonal ve bispesifik antikorlar geliştirmektedir. Daha fazla detay

CLDX temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 74.83% oranında artması öngörülüyor

Risk Analizi

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Celldex Therapeutics, Inc. Rakipler

Fusion Pharmaceuticals

NasdaqGS:FUSN

US$1.8b

Nurix Therapeutics

NasdaqGM:NRIX

US$1.6b

Deciphera Pharmaceuticals

NasdaqGS:DCPH

US$2.2b

Twist Bioscience

NasdaqGS:TWST

US$2.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Celldex Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$27.02
52 Haftanın En Yüksek Seviyesi	US$53.18
52 Haftanın En Düşük Seviyesi	US$22.93
Beta	1.59
11 Aylık Değişim	-5.76%
3 Aylık Değişim	-27.31%
1 Yıllık Değişim	-5.76%
33 Yıllık Değişim	-31.78%
5 Yıllık Değişim	1,025.83%
Halka arzdan bu yana değişim	-76.39%

Son Haberler & Güncellemeler

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15

Hissedar Getirileri

	CLDX	US Biotechs	US Pazar
7D	14.7%	2.4%	2.2%
1Y	-5.8%	16.2%	31.7%

Getiri vs. Endüstri: CLDX geçen yıl % 16.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: CLDX geçen yıl % 31.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CLDX's price volatile compared to industry and market?
CLDX volatility
CLDX Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: CLDX son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: CLDX 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1983	160	Anthony Marucci	www.celldex.com

Bir biyofarmasötik şirketi olan Celldex Therapeutics, Inc. çeşitli hastalıkların tedavisi için terapötik monoklonal ve bispesifik antikorlar geliştirmektedir. İlaç adayları arasında enflamatuar, alerjik, otoimmün ve diğer yıkıcı hastalıkları olan hastaları tedavi etmek için antikor bazlı terapötikler bulunmaktadır. Şirketin klinik geliştirme programları, reseptör tirozin kinaz KIT'i bağlayan ve aktivitesini inhibe eden bir Faz II monoklonal antikor olan CDX-0159'dur.

Celldex Therapeutics, Inc. Temel Bilgiler Özeti

Celldex Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CLDX temel i̇stati̇sti̇kler
Piyasa değeri	US$1.74b
Kazançlar(TTM)	-US$154.08m
Gelir(TTM)	US$9.98m

179.7x

P/S Oranı

-11.6x

F/K Oranı

CLDX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CLDX gelir tablosu (TTM)
Gelir	US$9.98m
Gelir Maliyeti	US$147.04m
Brüt Kâr	-US$137.06m
Diğer Giderler	US$17.02m
Kazançlar	-US$154.08m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.32
Brüt Marj	-1,373.91%
Net Kâr Marjı	-1,544.48%
Borç/Özkaynak Oranı	0%

CLDX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CLDX Stoklara Genel Bakış

Ödüller

Risk Analizi

Celldex Therapeutics, Inc. Rakipler

NasdaqGS:FUSN

US$1.8b

NasdaqGM:NRIX

US$1.6b

NasdaqGS:DCPH

US$2.2b

NasdaqGS:TWST

US$2.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

Recent updates

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 65%, EPS downgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Price target decreased by 7.6% to US$65.38

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Consensus revenue estimates decrease by 20%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 9.7% to US$69.43

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Consensus revenue estimates increase by 37%, EPS downgraded

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Price target increased by 7.4% to US$64.00

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

Price target decreased by 7.4% to US$59.57

Consensus revenue estimates decrease by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Now 20% undervalued after recent price drop

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

Consensus revenue estimates increase by 68%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Now 23% undervalued

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors